Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
暂无分享，去创建一个
[1] G. Nyberg. CURRENT STATUS OF ISOSORBIDE‐5-MONONITRATE THERAPY IN CHRONIC STABLE ANGINA PECTORIS , 1994, American journal of therapeutics.
[2] S. Glasser,et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. , 1993, The American journal of cardiology.
[3] M. Soliva,et al. Isosorbide 5‐mononitrate and isosorbide 2‐mononitrate kinetics after intravenous and oral dosing , 1984, Clinical pharmacology and therapeutics.
[4] L. F. Chasseaud,et al. Isosorbide 5‐mononitrate kinetics , 1984, Clinical pharmacology and therapeutics.
[5] M. Gibaldi,et al. Noncompartmental Analysis Based on Statistical Moment Theory , 1982 .
[6] L. F. Chasseaud,et al. Isosorbide 5-mononitrate pharmacokinetics in humans. , 1981, Biopharmaceutics & drug disposition.
[7] J. Sjögren. Studies on a sustained release principle based on an inert plastic matrix. , 1971, Acta pharmaceutica Suecica.
[8] H. Laufen,et al. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. , 1983, Arzneimittel-Forschung.